Breaking News

Evotec Earns Boehringer Milestone

June 23, 2014

Transitions compound into preclinical development

Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of €1.0 million. Evotec transitioned a back-up compound from a respiratory program into preclinical development.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, "We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully."
 
The companies entered the multi-year, multi-target drug discovery alliance in 2004 to jointly identify and develop candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.

blog comments powered by Disqus